PD 153035
(Synonyms: 4-[(3-溴苯基)氨基]-6,7-二甲氧基喹啉,SU-5271; AG1517; ZM 252868) 目录号 : GC49617
A potent EGFR kinase inhibitor
Cas No.:153436-54-5
Sample solution is provided at 25 µL, 10mM.
PD 153035 is a potent, reversible inhibitor of EGFR kinase (Ki = 5.2 pM; IC50 = 29 pM).1 It less effectively inhibits HER2 (IC50 = 2.3 µM) and has little effect on several other receptor and non-receptor tyrosine kinases.1 PD 153035 has been shown to rapidly suppress autophosphorylation of EGFR in ?broblasts and human epidermoid carcinoma cells, as well as to selectively block EGF-mediated cellular processes, including mitogenesis and early gene expression.2,3
1.Fry, D.W., Kraker, A.J., McMichael, A., et al.A specific inhibitor of the epidermal growth factor receptor tyrosine kinaseScience265(5175)1093-1095(1994) 2.Bos, M., Mendelsohn, J., Kim, Y.M., et al.PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent mannerClinical Cancer Research3(11)2099-2106(1997) 3.Rae, J.M., and Lippman, M.E.Evaluation of novel epidermal growth factor receptor tyrosine kinase inhibitorsBreast Cancer Research and Treatment83(2)99-107(2004)
Cas No. | 153436-54-5 | SDF | Download SDF |
别名 | 4-[(3-溴苯基)氨基]-6,7-二甲氧基喹啉,SU-5271; AG1517; ZM 252868 | ||
Canonical SMILES | COC(C(OC)=C1)=CC2=C1N=CN=C2NC3=CC(Br)=CC=C3 | ||
分子式 | C16H14BrN3O2 | 分子量 | 360.2 |
溶解度 | DMF: 0.3 mg/ml,DMSO: 2 mg/ml,DMSO:PBS (pH 7.2)(1:8): 0.11 mg/ml,Ethanol: 0.2 mg/ml | 储存条件 | -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 2.7762 mL | 13.8812 mL | 27.7624 mL |
5 mM | 0.5552 mL | 2.7762 mL | 5.5525 mL |
10 mM | 0.2776 mL | 1.3881 mL | 2.7762 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet